{"success":true,"data":{"pressRelease":{"id":"169700","rtpr_id":"nGNE2BnHsd-20261015","ticker":"IBAB","exchange":"","all_tickers":["IBAB"],"title":"REG-IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems","author":"Globe Newswire","published_at":"2026-10-15T05:00:00.051Z","article_body":"IBA is preferred supplier for a 12-system national PET radiopharmaceutical\nproduction network, securing capacity ahead of demand across diagnostics and\ntheranostics\n\nLouvain-la-Neuve, Belgium – October 15, 2026, 7 a.m. – IBA (Ion Beam\nApplications S.A., EURONEXT), the world leader in particle accelerator\ntechnology and the world’s leading provider of radiopharmaceutical\nproduction solutions, today announced that a leading global producer and\ndistributor of radiopharmaceuticals has selected IBA as preferred vendor for\nthe expansion of its production network in the United States with an order of\n12 Cyclone(®) KIUBE 300 solutions to secure the production of radioisotopes\nfor diagnostic and therapeutic applications.\n\nIndustrial capacity has become the gating factor in radiopharmaceuticals\ntoday. Clinical pipelines are broadening across both diagnostics and therapy,\nwhile supply, licensing and production capacity set the pace at which they\nreach patients. The new collaboration between this leading global producer and\nIBA answers that need directly: production capacity secured at network scale\nin the largest radiopharmaceutical market, with every system configured for\nfluorine-18 ((18)F) volume today and for radiometals as the therapeutic\npipeline matures. The collaboration represents a capacity commitment made\nahead of demand rather than in reaction to it.\n\nThis contract covers an order for 12 Cyclone(®) KIUBE 300 systems, each\nequipped with multiple Nirta(®) HCFT (18)F helium cooling free targets as\nwell as service like IntegraLab(®) facility design, installation and\ncommissioning, KARE Portal access, and operator and maintenance training. The\nsystems will be deployed as a national production network across multiple\nsites in the United States, intended for high-volume commercial PET tracer\nproduction with (18)F at the core.\n\nLoïk-Maël Nys, President of IBA RadioPharma Solutions commented: “We are\npleased to have been selected by one of the world’s key players in the\nproduction of radiopharmaceuticals to support their expansion plan in the\nUnited States. Deploying 12 high-output cyclotrons across a national network\nwithin a short timeframe is a significant undertaking, reflecting IBA's unique\nability to manufacture at scale, execute consistently and integrate the\nservices required to design, install, commission and support production\nfacilities over time. This collaboration also reflects our commitment to\nproviding solutions that bring better outcomes to patients. We look forward to\ncontinuing to work together and help expand access to life-changing diagnostic\nand therapeutic radiopharmaceuticals, in the US and beyond.”\n\nIBA's advanced technologies expertise\nIBA is a leading supplier of PET and SPECT cyclotrons, with more than 350\nsystems installed worldwide. It is the only supplier able to cover the full 9\nto 70 MeV range, with upgrades available on a CAPEX-only basis over 20 years.\nEach IBA system is supported with two decades of servicing, spare-parts supply\nand upgrade activities. Its advanced technology is backed on the ground by an\nefficient locally integrated service organisation with more than 40 years in\nthe market, dedicated field engineers and a dedicated area spare parts hub.\n\nThe Cyclone(®) KIUBE platform delivers on both performance and reliability:\nthe system can produce up to 35 Ci of (18)F in a single two-hour dual beam\nrun, driving +42% FDG revenue and +76% FDG EBIT per site compared with the\nleading competing platform. Fleet uptime remains above 97%, thanks to\nredundancy built into every main subsystem.\n\nCyclone(®) KIUBE 300 system typically ranges in price from € 2,5 to 5\nmillion depending on configuration and options.\n\n***ENDS***\n\nAbout IBA\n\nIBA (Ion Beam Applications S.A.) is the world leader in particle accelerator\ntechnology. The company is the leading supplier of equipment and services in\nthe fields of proton therapy, considered one of the most advanced forms of\nradiation therapy available today, as well as industrial sterilization,\nradiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve,\nBelgium, employs approximately 2,300 people worldwide. IBA is a certified B\nCorporation (B Corp) meeting the highest standards of verified social and\nenvironmental performance.\n\nIBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters\nIBAB.BR and Bloomberg IBAB.BB). More information can be found at:\nwww.iba-worldwide.com.\n\nCONTACTS\nThomas Pevenage\nInvestor Relations\n+32 10 475 890\ninvestorrelations@iba-group.com\n\nNathalie van Ypersele\nHead of Communication and Sustainability\n\nDaniel Ernult \nCorporate Communication Manager\n+32 10 475 890\ncommunication@iba-group.com\n\nAttachment\n*     20261015-IBA-12-KIUBE-contract-EN\n(https://ml-eu.globenewswire.com/Resource/Download/1ddf18ff-ad44-4260-b6d8-694dcdb06b87)","article_body_html":"","raw_payload":{"data":{"id":"nGNE2BnHsd-20261015","title":"REG-IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems","author":"Globe Newswire","ticker":"IBAB","created":"2026-10-15T05:00:00.051Z","tickers":["IBAB"],"exchange":"","article_body":"IBA is preferred supplier for a 12-system national PET radiopharmaceutical\nproduction network, securing capacity ahead of demand across diagnostics and\ntheranostics\n\nLouvain-la-Neuve, Belgium – October 15, 2026, 7 a.m. – IBA (Ion Beam\nApplications S.A., EURONEXT), the world leader in particle accelerator\ntechnology and the world’s leading provider of radiopharmaceutical\nproduction solutions, today announced that a leading global producer and\ndistributor of radiopharmaceuticals has selected IBA as preferred vendor for\nthe expansion of its production network in the United States with an order of\n12 Cyclone(®) KIUBE 300 solutions to secure the production of radioisotopes\nfor diagnostic and therapeutic applications.\n\nIndustrial capacity has become the gating factor in radiopharmaceuticals\ntoday. Clinical pipelines are broadening across both diagnostics and therapy,\nwhile supply, licensing and production capacity set the pace at which they\nreach patients. The new collaboration between this leading global producer and\nIBA answers that need directly: production capacity secured at network scale\nin the largest radiopharmaceutical market, with every system configured for\nfluorine-18 ((18)F) volume today and for radiometals as the therapeutic\npipeline matures. The collaboration represents a capacity commitment made\nahead of demand rather than in reaction to it.\n\nThis contract covers an order for 12 Cyclone(®) KIUBE 300 systems, each\nequipped with multiple Nirta(®) HCFT (18)F helium cooling free targets as\nwell as service like IntegraLab(®) facility design, installation and\ncommissioning, KARE Portal access, and operator and maintenance training. The\nsystems will be deployed as a national production network across multiple\nsites in the United States, intended for high-volume commercial PET tracer\nproduction with (18)F at the core.\n\nLoïk-Maël Nys, President of IBA RadioPharma Solutions commented: “We are\npleased to have been selected by one of the world’s key players in the\nproduction of radiopharmaceuticals to support their expansion plan in the\nUnited States. Deploying 12 high-output cyclotrons across a national network\nwithin a short timeframe is a significant undertaking, reflecting IBA's unique\nability to manufacture at scale, execute consistently and integrate the\nservices required to design, install, commission and support production\nfacilities over time. This collaboration also reflects our commitment to\nproviding solutions that bring better outcomes to patients. We look forward to\ncontinuing to work together and help expand access to life-changing diagnostic\nand therapeutic radiopharmaceuticals, in the US and beyond.”\n\nIBA's advanced technologies expertise\nIBA is a leading supplier of PET and SPECT cyclotrons, with more than 350\nsystems installed worldwide. It is the only supplier able to cover the full 9\nto 70 MeV range, with upgrades available on a CAPEX-only basis over 20 years.\nEach IBA system is supported with two decades of servicing, spare-parts supply\nand upgrade activities. Its advanced technology is backed on the ground by an\nefficient locally integrated service organisation with more than 40 years in\nthe market, dedicated field engineers and a dedicated area spare parts hub.\n\nThe Cyclone(®) KIUBE platform delivers on both performance and reliability:\nthe system can produce up to 35 Ci of (18)F in a single two-hour dual beam\nrun, driving +42% FDG revenue and +76% FDG EBIT per site compared with the\nleading competing platform. Fleet uptime remains above 97%, thanks to\nredundancy built into every main subsystem.\n\nCyclone(®) KIUBE 300 system typically ranges in price from € 2,5 to 5\nmillion depending on configuration and options.\n\n***ENDS***\n\nAbout IBA\n\nIBA (Ion Beam Applications S.A.) is the world leader in particle accelerator\ntechnology. The company is the leading supplier of equipment and services in\nthe fields of proton therapy, considered one of the most advanced forms of\nradiation therapy available today, as well as industrial sterilization,\nradiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve,\nBelgium, employs approximately 2,300 people worldwide. IBA is a certified B\nCorporation (B Corp) meeting the highest standards of verified social and\nenvironmental performance.\n\nIBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters\nIBAB.BR and Bloomberg IBAB.BB). More information can be found at:\nwww.iba-worldwide.com.\n\nCONTACTS\nThomas Pevenage\nInvestor Relations\n+32 10 475 890\ninvestorrelations@iba-group.com\n\nNathalie van Ypersele\nHead of Communication and Sustainability\n\nDaniel Ernult \nCorporate Communication Manager\n+32 10 475 890\ncommunication@iba-group.com\n\nAttachment\n*     20261015-IBA-12-KIUBE-contract-EN\n(https://ml-eu.globenewswire.com/Resource/Download/1ddf18ff-ad44-4260-b6d8-694dcdb06b87)"},"type":"article","timestamp":"2026-10-15T05:00:00.148375379Z","server_sent_at_ms":1792040400148},"received_at":"2026-10-15T05:00:00.196Z","source_url":null},"analysis":{"id":"157932","press_release_id":"169700","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"IBA has been named preferred vendor by a leading global radiopharmaceutical producer for a 12-system order of Cyclone KIUBE 300 cyclotrons to build out a national US PET production network.\n\nEach system carries Nirta (18)F targets plus IntegraLab design, installation, commissioning and training services; at the stated €2.5-5 million per-unit price, the implied order value is roughly €30-60 million before services.\n\nThe deal underscores IBA's scale in radiopharma equipment, with the platform claiming +42% FDG revenue and +76% FDG EBIT per site versus the leading competing system and fleet uptime above 97%.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Capacity-ahead-of-demand: IBA locks a 12-cyclotron US network order with an unnamed global radiopharma leader."},"keyFigures":{"customDimensions":{"fleet_uptime":"above 97%","fdg_ebit_uplift":"+76%","systems_ordered":12,"fdg_revenue_uplift":"+42%","fl18_output_per_run":"up to 35 Ci","implied_order_value_eur":"€30-60 million","per_unit_price_range_eur":"€2.5 to 5 million"}},"quotedText":"Deploying 12 high-output cyclotrons across a national network within a short timeframe is a significant undertaking, reflecting IBA's unique ability to manufacture at scale, execute consistently and integrate the services required to design, install, commission and support production facilities over time.","namedEntities":{"people":[{"name":"Loïk-Maël Nys","role":"President of IBA RadioPharma Solutions"},{"name":"Thomas Pevenage","role":"Investor Relations"}],"products":["Cyclone KIUBE 300","Nirta HCFT (18)F helium cooling free targets","IntegraLab","KARE Portal"],"companies":[{"name":"IBA (Ion Beam Applications S.A.)","ticker":"IBAB","relationship":"filer/supplier"}],"dollarAmounts":[{"amount":"€ 2,5 to 5 million","context":"typical price range per Cyclone KIUBE 300 system"}]},"materialImpact":{"score":3,"reasoning":"A 12-system order for Cyclone KIUBE 300 cyclotrons (implied €30-60M range based on stated per-unit pricing) plus attached services secures a national US network for IBA. Material contract win for a mid-cap equipment maker, but not a market-moving binary event."},"tickerRelevance":{"others":[],"primary":"IBAB"},"globalImportance":35,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap foreign-listed (Euronext)","eventGravity":"material contract win","sectorWeight":"medical equipment","customerDisclosed":false}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"IBA has been named preferred vendor by a leading global radiopharmaceutical producer for a 12-system order of Cyclone KIUBE 300 cyclotrons to build out a national US PET production network.\n\nEach system carries Nirta (18)F targets plus IntegraLab design, installation, commissioning and training services; at the stated €2.5-5 million per-unit price, the implied order value is roughly €30-60 million before services.\n\nThe deal underscores IBA's scale in radiopharma equipment, with the platform claiming +42% FDG revenue and +76% FDG EBIT per site versus the leading competing system and fleet uptime above 97%.","key_figures":{"customDimensions":{"fleet_uptime":"above 97%","fdg_ebit_uplift":"+76%","systems_ordered":12,"fdg_revenue_uplift":"+42%","fl18_output_per_run":"up to 35 Ci","implied_order_value_eur":"€30-60 million","per_unit_price_range_eur":"€2.5 to 5 million"}},"named_entities":{"people":[{"name":"Loïk-Maël Nys","role":"President of IBA RadioPharma Solutions"},{"name":"Thomas Pevenage","role":"Investor Relations"}],"products":["Cyclone KIUBE 300","Nirta HCFT (18)F helium cooling free targets","IntegraLab","KARE Portal"],"companies":[{"name":"IBA (Ion Beam Applications S.A.)","ticker":"IBAB","relationship":"filer/supplier"}],"dollarAmounts":[{"amount":"€ 2,5 to 5 million","context":"typical price range per Cyclone KIUBE 300 system"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T05:00:06.483Z","global_importance":35,"audience_relevance":20,"importance_components":{"tickerTier":"mid-cap foreign-listed (Euronext)","eventGravity":"material contract win","sectorWeight":"medical equipment","customerDisclosed":false}},"durationMs":6269,"modelName":"glm-5.3-flashx"}}